Abstract
This report provides recommendations for use of the newly licensed hepatitis A vaccines (HAVRIX, manufactured by SmithKline Beecham Biologicals, and VAQTA, manufactured by Merck & Company, Inc.) in persons > or = 2 years of age and updates previous recommendations for use of immune globulin (IG) for protection against hepatitis A (superseding MMWR 1990;39[No. RR-2]:1-5). For preexposure protection, hepatitis A vaccine can now be used instead of IG in many circumstances; for postexposure prophylaxis, the recommendations for IG use are unchanged.
Publication types
-
Guideline
-
Practice Guideline
MeSH terms
-
Adolescent
-
Adult
-
Child
-
Child, Preschool
-
Disease Outbreaks
-
Female
-
Hepatitis A / diagnosis
-
Hepatitis A / epidemiology
-
Hepatitis A / prevention & control*
-
Hepatitis A / transmission
-
Hepatitis A Vaccines
-
Hepatitis A Virus, Human / immunology*
-
Humans
-
Immunization, Passive / standards*
-
Immunoglobulins / administration & dosage*
-
Male
-
Middle Aged
-
Population Surveillance
-
Risk Factors
-
Seroepidemiologic Studies
-
United States / epidemiology
-
Vaccination / standards*
-
Vaccines, Inactivated / administration & dosage*
-
Vaccines, Inactivated / immunology
-
Viral Hepatitis Vaccines / administration & dosage*
-
Viral Hepatitis Vaccines / immunology
Substances
-
Hepatitis A Vaccines
-
Immunoglobulins
-
Vaccines, Inactivated
-
Viral Hepatitis Vaccines